GABRIELLE RUTHERFORD: Open Payments
NPI 1609227974 · COVINGTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,637 in 63 payments from 15 companies in 2025. Trend: 2023 $984 · 2024 $1,349 · 2025 $1,637
Food & beverage: $1,637
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 11 | $451 |
| AstraZeneca Pharmaceuticals LP | 12 | $364 |
| GlaxoSmithKline, LLC. | 14 | $216 |
| Verona Pharma, Inc. | 10 | $150 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $138 |
| GENZYME CORPORATION | 3 | $67 |
| ANI Pharmaceuticals, Inc. | 2 | $57 |
| Calliditas Therapeutics US Inc. | 2 | $54 |
| Novo Nordisk Inc | 1 | $28 |
| Viatris Specialty LLC | 1 | $28 |
Products named: DUPIXENT, BREZTRI, Ohtuvayre, NUCALA, TRELEGY ELLIPTA, AIRSUPRA, PURIFIED CORTROPHIN GEL, TARPEYO.
Industry payments across LA — which companies pay providers there.
